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Abstract
Background: The chick chorio-allantoic membrane (CAM) assay is a commonly used method for studying
angiogenic or anti-angiogenic activities in vivo. The ease of access allows direct monitoring of tumour growth by
biomicroscopy and the possibility to screen many samples in an inexpensive way. The CAM model provides a
powerful tool to study effects of molecules, which interfere with physiological angiogenesis, or experimental
tumours derived from cancer cell lines. We therefore screened eight osteosarcoma cell lines for their ability to form
vascularized tumours on the CAM.
Findings: We implanted 3-5 million cells of human osteosarcoma lines (HOS, MG63, MNNG-HOS, OST, SAOS, SJSA1,
U2OS, ZK58) on the CAM at day 10 of embryonic development. Tumour growth was monitored by in vivo
biomicroscopy at different time points and tumours were fixed in paraformaldehyde seven days after cell grafting.
The tissue was observed, photographed and selected cases were further analyzed using standard histology.
From the eight cell lines the MNNG-HOS, U2OS and SAOS were able to form solid tumours when grafted on the
CAM. The MNNG-HOS tumours showed the most reliable and consistent growth and were able to penetrate the
chorionic epithelium, grow in the CAM stroma and induce a strong angiogenic response.
Conclusions: Our results show that the CAM assay is a useful tool for studying osteosarcoma growth. The model
provides an excellent alternative to current rodent models and could serve as a preclinical screening assay for
anticancer molecules. It might increase the speed and efficacy of the development of new drugs for the treatment
of osteosarcoma.
Introduction
Osteosarcoma is the most common primary malignant
bone tumour that usually affects children and adoles-
cents. After the introduction of cytotoxic polyche-
motherapy to the treatment of osteosarcoma
tremendous advances were achieved, increasing the sur-
vival rate from under 20% to over 60%[1]. But over the
past 20 years no substantial improvements were made.
There is still a high failure rate especially when metas-
tases are present[2]. It is therefore of critical importance
to identify new targets and new molecules with efficient
antitumour activity. New targets might be identified by
large-scale microarray analysis or array-based genomic
hybridization[3] to identify different gene expressions in
patient samples or suitable in vivo animal models. It is
expected that anti-angiogenic agents will have clinical
benefits for patients with osteosarcoma, probably by
reducing metastasis[4]. Thus especially models that
allow precise monitoring of tumour angiogenesis might
be promising in finding new targets to treat osteosar-
coma[5].
An in vivo assay to serve these purposes is the chick
chorio-allantoic membrane (CAM) assay. The CAM is
formed on embryonic day 4 - 5 by fusion of the chorion
with the allantoic vesicle[6]. The resulting membrane
consists of two mesodermal layers: the somatic meso-
derm of the chorion and the splanchnic mesoderm of
the allantois. In this structure, an extremely dense vas-
cular network develops with bigger vessels located
within the mesoderm and the capillaries situated directly
under or within a very thin ectodermal layer. The phy-
siological role of the CAM is to serve as a respiratory
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absorb calcium from the shell for bone development[7].
On the molecular level critical genes which participate
in the vascularisation of complex human tissues such as
placenta and the lung are significantly regulated during
the CAM vascular development[8]. The CAM assay is
characterized by several major advantages such as the
ease of access, the extensive vascularisation and the rela-
tively simple experimental approach. This opens up the
possibility to screen many samples in an inexpensive
way[9].
Since its use to demonstrate normal embryonic blood
vessel development more than 100 years ago, the CAM
served as a host for transplantations of embryonic tissue
as well as for bacteria and viruses. During the last 20
years the CAM is extensively used in angiogenesis
research but a reliable bone tumour model has not yet
been reported.
Here we present the results of the screening of the
human osteosarcoma cell lines HOS, MG63, MNNG-
HOS, OST, SAOS, SJSA1, U2OS and ZK58 for their use
i nt h eC A Ma s s a ya n dp r o v i d ee v i d e n c et h a tt h e
MNNG-HOS cell line reproducibly simulates key fea-
tures of human osteosarcoma growth.
Materials and methods
Cell culture
Eight osteosarcoma cell lines (HOS, MG63, MNNG-
HOS, OST, SAOS, SJSA1, U2OS, ZK58) were used in
this study. All cell lines were cultured in RPMI 1640
(E15-840, PAA Austria) supplemented with 10% Fetal
Bovine Serum (FBS Gold, A15-649, PAA Austria) and
1% penicilline/streptomycine (P11-010, PAA Austria) at
37°C in a humidified 5% CO2 incubator. Prior implanta-
tion, cell suspensions were prepared by detaching cells
with trypsin/EDTA (L11-004, PAA Austria). Cells were
centrifuged at 1200 rpm for 5 min, washed twice in cul-
ture medium and resuspended in medium at a final con-
centration of 3 to 5 million cells per 20 μl[10].
CAM assay
Fertilized white leghorn chicken eggs (Lohmann Tierzucht
GmbH, Cuxhaven, Germany) were incubated at a humid-
ity of 70% and 37°C. On day 3 of incubation, a round win-
dow was cut into the shell after removal of 2 - 3 ml of
albumen allowing detachment of the embryo from the
eggshell. Normal development was verified and embryos
with malformations or dead embryos were excluded. The
window was sealed with tape and the eggs were returned
to the incubator. On day 10 of development, small plastic
rings made out of Thermanox™ discs were placed on the
CAM and 25 μl of medium containing different cell lines
were deposited into the rings after gentle laceration of the
CAM surface. The number of CAMs implanted for each
cell line is indicated in Table 1. CAMs were examined
daily until day 17 and photographed in ovo with a digital
camera (Olympus E330) attached to a stereomicroscope.
CAMs were checked for tumour growth. Positive tumour
development ("+” tumours) was reported when tumour
angiogenesis was visible and when tumours were bigger
than 2 mm. All other tumours were classified as ("-”). The
estimated tumour volume was calculated (according to
Hagedorn et al 2005[10]) by the following formula: V = 4/
3* π *r
3 (r = 1/2 * square root of diameter 1 * diameter 2).
Frequently several independent tumour nodules devel-
oped. However for quantification only the biggest nodule
was taken. Only CAMs still alive at day 17 were included
in this analysis.
Statistical analysis
To determine if osteosarcoma growth on the CAM was
associated with increased embryonic death, a 2 × 2 con-
tingency table test (Fisher’s exact test) was used for each
cell line compared to control CAMs.
Histology
On embryonic day 17, a few ml of 4% paraformaldehyde
were put onto the CAM after photo documentation.
After 20 min the window was carefully enlarged using
scissors without destroying the CAM. Areas containing
the tumour were cut out and transferred into culture
discs. All tumours were evaluated and relevant samples
were embedded in paraffin and processed for sectioning.
Embedded tumours were cut into 10 μm sections,
stained with hematoxylin-eosin and further analysed by
standard light microscopy (Leica DM2500 with Leica
EC3 camera).
Results
From the eight cell lines tested only the MNNG-HOS,
U 2 O Sa n dS A O Sl i n ec o n s i s t e n t l y( =m o r et h a ni n5 0 %
of the cases alive at day 17) formed vascularized
tumours of more than 2 mm in size (Figure 1). In all
other cell lines, the tumours where either smaller or did
not develop at all (Table 1). Grafting of the U2OS and
SAOS cell lines was significantly associated with
increased embryonic death, compared to non-grafted
CAMs (P-values: 0.0294 and 0.0008, respectively).
MNNG-HOS, U2OS and SAOS tumours revealed a
reproducible growth pattern after implantation of the
cells. After 4 days, a vascularized tumour became appar-
ent. Growth and vascularization of the tumour steadily
progressed until day 7 as evidenced by biomicroscopy
( F i g u r e2 A - C ) .I ns o m ec a s es of MNNG-HOS tumours,
growth was associated with bleeding (Figure 2C-E).
Furthermore, MNNG-HOS tumours showed an invasive
growth pattern and were able to penetrate the CAM
and grow underneath it. This was not observed in the
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the CAM or within the membrane. This became clearly
apparent when the membrane was cut out after fixation
and turned upside down (Figure 2D-G). The surround-
ing vessels were attracted towards the tumour tissue. At
higher magnification, blood flow could be observed, a
direct evidence of the functionality of the tumour capil-
laries (data not shown). Biomicroscopy of the tumours
revealed a very rich vascularisation showing signs of
active sprouting angiogenesis (Figure 2G).
Standard histology with hematoxylin-eosin staining
confirmed the rich vascularisation of the tumours with
capillaries sprouting out of the CAM into the tumour
(Figure 3A, B). Nucleated chick erythrocytes were pre-
sent in the capillaries (Figure 3C). The tumours con-
tained stromal cells with disseminated uncharacterized
macrophages. Areas of angiogenesis, necrosis and hae-
morrhage were present, a typical feature of human
osteosarcoma (Figure 3B + C). Osteoid formation did
not occur in any cell line. Controls with medium alone
did not show any tissue growth, inflammatory reaction
or vascular response.
Discussion
Experimental in vivo tumour models are essential for
comprehending the dynamic process of human cancer
progression, identifying therapeutic targets, and evaluat-
ing antitumour drugs. Besides the promising efforts
made in the research on osteosarcoma using in vitro
assays[11] there is a lack of potent and reproducible in
vivo models to evaluate new therapies in a pre-clinical
setting.
The chick chorioallantoic membrane assay is a com-
monly used method for studying angiogenic or anti-
angiogenic activities in vivo[12]. Although first tumour
transplantations to the CAM were described more than
100 years ago[13] CAM tumour models are still rarely
developed and characterized, compared to murine mod-
els[14]. Taking into account the easy access, relatively
simple experimental approach and the natural immono-
deficient environment of the developing embryo (for
review see[15]) its rare use for tumour grafting is sur-
prising. Recently, a reliable experimental glioblastoma
CAM model using the human U87 cell line has been
established[10]. The experimental glioma model simu-
lates key features of human glioma growth in a few
days. Treatment with the tyrosine kinase inhibitors
Gleevec (imatinib) or PTK787/ZK 222584, siRNA-
mediated knock down of Vascular Endothelial Growth
Factor (VEGF) and/or IL6[16,17] potently inhibited
tumour angiogenesis and growth in this model.
Another group inoculated single cell suspensions of
LNCaP, PC-3 and Tsu-Pr1 human prostatic cancer cell
lines on the chorio-allantoic membrane. They demon-
strated a reliable tumour growth allowing the evaluation
of proliferation and apoptosis induction after intravascu-
lar or topic application of anticancer drugs[18].
There are very few publications about the use of the
CAM assay in human bone or soft tissue sarcoma
[19,20]. The literature does not provide any reports that
specifically characterise the tumour forming potential of
different human osteosarcoma cell lines. Therefore, we
established a protocol allowing monitoring of the
growth of several osteosarcoma lines on the CAM. The
MNNG-HOS, U2OS and SAOS cell lines consistently
developed vascularized tumours after 4 days, which then
progressively consolidated throughout the growth pro-
cess. All tumours were derived from established human
osteosarcoma cell lines [21-24] and were more or less
able to form a solid tumour, but only the MNNG-HOS,
SAOS and U2OS reached the consistency as well as
average tumour size (Figure 1G) to allow further investi-
gations. The MNNG-HOS cells clearly provided the
most reliable and consistent results. The reasons for
these differences remain speculative. The difference of
up to two million cells between CAM’s from different
experiments might partly explain the size variances, but
it is rather unlikely as this would affect all cell lines. It
Table 1 Overview of tested osteosarcoma cell lines
Cell line Number of grafted CAMs Embryos died Number of - tumours Number of + tumours Ratio +/- % dead P-value*
MNNG-HOS 23 6 6 11 11/17 26.1 NS
U2OS 21 11 5 5 5/10 52.4 0.0294
SAOS 20 14 3 3 3/6 70 0.0008
OST 8 2 5 1 1/6 25 NS
MG63 14 7 4 1 1/7 50 NS
HOS 20 5 13 2 2/15 25 NS
ZK58 35 11 21 3 3/24 31.4 NS
SJ-SA-1 11 2 9 0 0/9 18.2 NS
Controls 26 5 19.2
n = number, - = no tumour/tumour ≤ 2 mm, + = vascularized tumour > 2 mm
*Fisher’s exact test (cell line vs. controls); NS = not significant
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produces a differently composed extracellular matrix[21]
and thus might have a different potential to degrade the
CAM tissue. Possibly only the more aggressive cell lines
are able to invade the CAM and induce angiogenesis,
which is essential for tumour growth. The MNNG-HOS
cell line is derived from HOS cells by treatment with
the carcinogenic nitrosamine MNNG[25], and was
shown to have a high degree of similarity but also some
characteristic differences from the maternal cell line[22]
that did not grow well in our model. The fact that a sig-
nificantly higher mortality rate was seen after grafting of
SAOS and U2OS cells (both reliably formed tumours)
may be due to tumour cell dissemination in the embryo
or secretion of factors which cause blood coagulation.
Secretion of such molecules by cancer cells is favoured
Figure 1 Tumours of three different cell lines grown on the CAM. In vivo microscopy of tumours grown of indicated cell lines after 7 days
of tumour growth. A - C: magnification 10× (scale bar 1 mm), D - E: higher magnification (40×, scale bar 250 μm) of A - C. G: Graph illustrating
the mean tumour volumes calculated by the following formula: V = 4/3*π*r
3 (r = 1/2 * square root of diameter 1 * diameter 2). SEM = standard
error of mean.
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Page 4 of 8Figure 2 Typical growth pattern of MNNG-HOS cells grafted to the CAM. A - C: In vivo microscopy (10×, scale bar 1 mm) documenting the
typical growth pattern after implantation of MNNG-HOS cells, arrowheads indicate tumour boundaries. A 1 day after grafting. After 4 days a
vascularized tumour becomes apparent (B). Solidification of the tumour steadily progresses until day 7 (C). Note the bleeding caused by the
tumour in C. D (12.5×, scale bar 0.8 mm) and E (50×, scale bar 20 μm) are higher magnifications of C after turning the CAM upside down. Note
the three smaller tumour nodules that were not visible from the upside (C). F (12.5×, scale bar 0.8 mm) and G (50×, scale bar 20 μm) is another
example of a typical MNNG-HOS tumour. Note the rich vascularization of the tumour (G).
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which might well occur during tumour cell implantation
on the CAM. Tsuchiya et al.[20] examined 24 human
tumour cell lines for their potential to form liver metas-
tases after injecting them into a larger CAM vessel.
They have shown that, among others, the MNNG-HOS
cells proliferated in the liver. The metastatic potential of
osteosarcoma cell lines (143B cells and to a lesser extent
MNNG-HOS cells) has also been shown in an orthoto-
pic mouse model[27] as well as in chick embryos after
intravascular injection in CAM veins[28]. Thus, this
model might also serve to study the development of dis-
tant metastases. Pulmonary metastases are very common
in osteosarcoma and are the typical cause of death in
human[1]. Also speculative at this point, they might also
be responsible for the significantly higher death rate in
the U2OS and SAOS treated embryos in our study.
The MNNG-HOS cells might be most suitable for
further inhibition studies in our model, since this line
reliably simulated key features of human osteosarcoma
growth such as angiogenesis, necrosis and haemorrhage.
Osteoid formation however, did not occur in this model.
This might be due to the lack of mature bone in the
developing chick embryo or due to the short time span
of only 7 days of tumour growth. The experimental
osteosarcoma described here are hybrid tumours: they
develop out of human cells and secondarily get invaded
by newly formed chicken capillaries and stromal cells,
therefore allowing further studies aiming at the molecu-
lar characterization of osteosarcoma angiogenesis. It
might for example be possible to separately study gene
expression in the newly formed vessels using Affymetrix
chicken GeneChips, in parallel with human GeneChips,
which will measure gene expression in the tumour cells.
This could lead to the development of new antitumour
drugs. The CAM model also is an attractive tool to fol-
low the fate and visualize microscopically the behaviour
of the grafted cells[14]. In vivo microscopy is possible at
every time point during the growth process, thus allow-
ing direct observations of tumour development and its
reactions to intravascular or topical application of antic-
ancer drugs. Additionally, intravital videomicroscopy of
Figure 3 Standard histology of MNNG-HOS tumour. Standard histology with hematoxylin-eosin staining confirming the rich vascularisation of
the tumours with capillaries originating from the CAM (arrows in A and B). The tumours also contain stromal cells with disseminated monocytes.
Areas of angiogenesis (arrowheads in B and C), necrosis and haemorrhage (asterisks in C) are present. A: Macroscopic picture, B: HE 10× (scale
bar 100 μm), C: HE 40× (scale bar 50 μm).
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focussing on metastasis formation. MacDonald et al.
used epifluorescence to identify labelled B16F1 mela-
noma cells, and studied successive stages of metastasis
formation in the CAM in vivo[29]. This might facilitate
the screening of new therapeutic approaches[30] such as
molecules targeting the RANK/RANKL/OPG axis[31].
A limit of this model is the short time span of only 7
days for tumour growth which might not have been
long enough for the other cell lines to grow to bigger
tumours. However, especially this time frame might be
of importance for the development of metastases or
tumour recurrence. These first steps are heavily depen-
dent on invasion and angiogenesis, which is a promising
target for new drugs against solid tumours, including
osteosarcoma[32,33].
Our model could serve as a preclinical screening assay
for anticancer molecules against osteosarcoma and
therefore increase the speed and efficacy of the develop-
ment of new drugs. More, the model is an excellent
alternative to rodent models and fits perfectly into cur-
rent recommendations of an ethically appreciable use of
live animals in cancer research[34].
Last, the experimental tumour model on the CAM
might be adapted for other malignant bone and soft-tis-
sue tumours such as chondrosarcoma, Ewing’s-sarcoma,
malignant fibrous histiocytosis, and benign but locally
aggressive lesions such as giant cell tumour of bone.
Acknowledgements
This work was supported by the EuroBoNet, a sixth framework priority
programme: LSH-2004-2.2.0-1 - Uncommon cancers in adults and children.
Special thanks go to Maryam Balke, MD, for critical review and correction of
the manuscript.
Author details
1Department of Orthopaedic Surgery, University of Muenster, Muenster,
Germany.
2Gerhard-Domagk-Institute of Pathology, University of Muenster,
Muenster, Germany.
3Institute of Pathology, Paderborn, Germany.
4Department of Orthopaedic Surgery, Orthopädische Klinik Volmarstein,
Wetter, Germany.
5INSERM U920 - Laboratoire des mécanismes moléculaires
de l’angiogenèse, University Bordeaux 1, Talence cedex, France.
Authors’ contributions
MB performed all CAM experiments and drafted the manuscript. AN did all
culturing of the cells and helped in drafting of the manuscript. CK and HB
did the histology and analysis of the tumours. KA helped with analysis and
interpretation of data. MH critically revised the manuscript and together
with MB is responsible for the study design. CG and GG participated in the
study design and coordination and helped in interpretation of the data. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 November 2009
Accepted: 4 March 2010 Published: 4 March 2010
References
1. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfurst C, Berger J,
Ritter J, Jurgens H, Gerein V: Neoadjuvant chemotherapy of
osteosarcoma: results of a randomized cooperative trial (COSS-82) with
salvage chemotherapy based on histological tumor response. J Clin
Oncol 1988, 6:329-337.
2. Casas-Ganem J, Healey JH: Advances that are changing the diagnosis and
treatment of malignant bone tumors. Curr Opin Rheumatol 2005, 17:79-85.
3. Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, Ladanyi M,
Gorlick R, Lau CC, Rao PH: Genome-wide array comparative genomic
hybridization analysis reveals distinct amplifications in osteosarcoma.
BMC Cancer 2004, 4:45.
4. Quan GM, Choong PF: Anti-angiogenic therapy for osteosarcoma. Cancer
Metastasis Rev 2006, 25:707-713.
5. Kreuter M, Bieker R, Bielack SS, Auras T, Buerger H, Gosheger G, Jurgens H,
Berdel WE, Mesters RM: Prognostic relevance of increased angiogenesis
in osteosarcoma. Clin Cancer Res 2004, 10:8531-8537.
6. DeFouw DO, Rizzo VJ, Steinfeld R, Feinberg RN: Mapping of the
microcirculation in the chick chorioallantoic membrane during normal
angiogenesis. Microvasc Res 1989, 38:136-147.
7. Rahn H, Paganelli CV, Ar A: The avian egg: air-cell gas tension,
metabolism and incubation time. Respir Physiol 1974, 22:297-309.
8. Javerzat S, Franco M, Herbert J, Platonova N, Peille AL, Pantesco V, De Vos J,
Assou S, Bicknell R, Bikfalvi A, Hagedorn M: Correlating global gene
regulation to angiogenesis in the developing chick extra-embryonic
vascular system. PLoS One 2009, 4:e7856.
9. Folkman J: Angiogenesis: initiation and control. Ann N Y Acad Sci 1982,
401:212-227.
10. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A,
Bikfalvi A: Accessing key steps of human tumor progression in vivo by
using an avian embryo model. Proc Natl Acad Sci USA 2005,
102:1643-1648.
11. Decker S, Winkelmann W, Nies B, van Valen F: Cytotoxic effect of
methotrexate and its solvent on osteosarcoma cells in vitro. J Bone Joint
Surg Br 1999, 81:545-551.
12. Hagedorn M, Balke M, Schmidt A, Bloch W, Kurz H, Javerzat S, Rousseau B,
Wilting J, Bikfalvi A: VEGF coordinates interaction of pericytes and
endothelial cells during vasculogenesis and experimental angiogenesis.
Dev Dyn 2004, 230:23-33.
13. Murphy JB, Rous P: The behavior of chicken sarcoma implanted in the
developing embryo. J Exp Med 1912, 119-132.
14. Deryugina EI, Quigley JP: Chick embryo chorioallantoic membrane model
systems to study and visualize human tumor cell metastasis. Histochem
Cell Biol 2008, 130:1119-1130.
15. Hagedorn M, Wilting J: Chick chorioallantoic membrane assay: growth factor
and tumor-induced angiogenesis and lymphangiogenesis Berlin, Heidelberg,
Germany: Springer 2004.
16. Saidi A, Javerzat S, Bellahcene A, De Vos J, Bello L, Castronovo V, Deprez M,
Loiseau H, Bikfalvi A, Hagedorn M: Experimental anti-angiogenesis causes
upregulation of genes associated with poor survival in glioblastoma. Int
J Cancer 2008, 122:2187-2198.
17. Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L, Bikfalvi A,
Javerzat S: Combined targeting of interleukin-6 and vascular endothelial
growth factor potently inhibits glioma growth and invasiveness. Int J
Cancer 2009, 125:1054-1064.
18. Kunzi-Rapp K, Genze F, Kufer R, Reich E, Hautmann RE, Gschwend JE:
Chorioallantoic membrane assay: vascularized 3-dimensional cell culture
system for human prostate cancer cells as an animal substitute model. J
Urol 2001, 166:1502-1507.
19. Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA,
Papagiannakopoulos T, Quigley JP: Unexpected effect of matrix
metalloproteinase down-regulation on vascular intravasation and
metastasis of human fibrosarcoma cells selected in vivo for high rates of
dissemination. Cancer Res 2005, 65:10959-10969.
20. Tsuchiya Y, Endo Y, Sato H, Okada Y, Mai M, Sasaki T, Seiki M: Expression of
type-IV collagenases in human tumor cell lines that can form liver
colonies in chick embryos. Int J Cancer 1994, 56:46-51.
21. Pautke C, Schieker M, Tischer T, Kolk A, Neth P, Mutschler W, Milz S:
Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in
comparison to human osteoblasts. Anticancer Res 2004, 24:3743-3748.
22. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U,
Mackintosh C, de Alava E, Myklebost O, Kresse SH, et al: Molecular
characterization of commonly used cell lines for bone tumor research: A
trans-European EuroBoNet effort. Genes Chromosomes Cancer 2009.
Balke et al. BMC Research Notes 2010, 3:58
http://www.biomedcentral.com/1756-0500/3/58
Page 7 of 823. Rodan SB, Imai Y, Thiede MA, Wesolowski G, Thompson D, Bar-Shavit Z,
Shull S, Mann K, Rodan GA: Characterization of a human osteosarcoma
cell line (Saos-2) with osteoblastic properties. Cancer Res 1987,
47:4961-4966.
24. Niforou KM, Anagnostopoulos AK, Vougas K, Kittas C, Gorgoulis VG,
Tsangaris GT: The proteome profile of the human osteosarcoma U2OS
cell line. Cancer Genomics Proteomics 2008, 5:63-78.
25. Rhim JS, Park DK, Arnstein P, Huebner RJ, Weisburger EK, Nelson-Rees WA:
Transformation of human cells in culture by N-methyl-N’-nitro-N-
nitrosoguanidine. Nature 1975, 256:751-753.
26. Denko NC, Giaccia AJ: Tumor hypoxia, the physiological link between
Trousseau’s syndrome (carcinoma-induced coagulopathy) and
metastasis. Cancer Res 2001, 61:795-798.
27. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, Yin H, Montag AG,
Simon MA, Peabody TD, et al: An orthotopic model of human
osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp
Metastasis 2005, 22:319-329.
28. Haeckel C, Krueger S, Roessner A: Antisense inhibition of urokinase: effect
on malignancy in a human osteosarcoma cell line. Int J Cancer 1998,
77:153-160.
29. MacDonald IC, Schmidt EE, Morris VL, Chambers AF, Groom AC: Intravital
videomicroscopy of the chorioallantoic microcirculation: a model system
for studying metastasis. Microvasc Res 1992, 44:185-199.
30. Khanna C: Novel targets with potential therapeutic applications in
osteosarcoma. Curr Oncol Rep 2008, 10:350-358.
31. Mori K, Berreur M, Blanchard F, Chevalier C, Guisle-Marsollier I, Masson M,
Redini F, Heymann D: Receptor activator of nuclear factor-kappaB ligand
(RANKL) directly modulates the gene expression profile of RANK-positive
Saos-2 human osteosarcoma cells. Oncol Rep 2007, 18:1365-1371.
32. Almog N, Henke V, Flores L, Hlatky L, Kung AL, Wright RD, Berger R,
Hutchinson L, Naumov GN, Bender E, et al: Prolonged dormancy of
human liposarcoma is associated with impaired tumor angiogenesis.
Faseb J 2006, 20:947-949.
33. Ma WW, Adjei AA: Novel agents on the horizon for cancer therapy. CA
Cancer J Clin 2009, 59:111-137.
34. Russell WMS, Burch RL: The Principles of Humane Experimental Technique
Potters Bar, UK: Universities Federation for Animal Welfare (UFAW), New
1992.
doi:10.1186/1756-0500-3-58
Cite this article as: Balke et al.: Morphologic characterization of
osteosarcoma growth on the chick chorioallantoic membrane. BMC
Research Notes 2010 3:58.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Balke et al. BMC Research Notes 2010, 3:58
http://www.biomedcentral.com/1756-0500/3/58
Page 8 of 8